Very efficient myoblast allotransplantation in mice under FK506 immunosuppression.
Transgenic CD1 mice expressing beta-galactosidase were used as myoblast donors. The myoblasts were injected in normal or mdx muscles previously irradiated and injected with notexin. Twenty-eight days after myoblast transplantation, the percentage of muscle fibers beta-glactosidase-positive was low in mice not immunosuppressed but was high (80%) in those treated with FK506. In mdx mice, muscle fibers expressing beta-galactosidase were also dystrophin positive. Most of the mice not treated with FK506 produced antibodies against the donor myoblasts. These results indicate that FK506 is a very useful immunosuppressive drug for myoblast transplantation in mice. Irradiation and notexin injection used in our experiments are, however, not feasible in humans. Other manipulations capable of increasing the participation of donor myoblasts to regeneration will therefore have to be identified before new clinical trials are attempted.
Kinoshita
I
I
Laboratoire de Neurobiologie, Université Laval, Hôpital de l'Enfant-Jésus, Québec, Canada.
Vilquin
J T
JT
Guérette
B
B
Asselin
I
I
Roy
R
R
Tremblay
J P
JP
D000818:Animals; D004546:Elapid Venoms / Q000633:toxicity; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D008214:Lymphocytes / Q000166:cytology; D008264:Macrophages / Q000166:cytology; D051379:Mice; D008810:Mice, Inbred C57BL; D018101:Mice, Inbred mdx; D008822:Mice, Transgenic; D009132:Muscles / Q000187:drug effects / Q000473:pathology / Q000637:transplantation*; D009498:Neurotoxins / Q000633:toxicity; D016559:Tacrolimus / Q000627:therapeutic use* / Q000633:toxicity; D014184:Transplantation, Homologous / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D001616:beta-Galactosidase / Q000032:analysis / Q000096:biosynthesis
D004546:Elapid Venoms; D009498:Neurotoxins; C005082:notexin; D001616:beta-Galactosidase; D016559:Tacrolimus